Mannkind (MNKD) closed at $4.13 on November 13, 2026, down 0.7% from the previous close, on volume of 1,557,274 shares (30-day average 3,543,485).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Calendar Put Spread | 15-Jan : 21-May-27 3 P | 1,000 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
MannKind to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 10-Nov 8:00 AM ET)
MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
Globe Newswire (Thu, 29-Oct 4:01 PM ET)
MannKind to Participate in the Chardan Healthcare Conference
Globe Newswire (Wed, 14-Oct 4:01 PM ET)
Globe Newswire (Fri, 9-Oct 8:00 PM ET)
Globe Newswire (Wed, 9-Sep 6:30 AM ET)
MannKind to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 8:30 AM ET)
MannKind's Ralinepag DPI Collaboration Points to Transformative Role in Pulmonary Hypertension Care
Market Chameleon (Wed, 6-May 6:30 AM ET)
Market Chameleon (Mon, 26-Jan 3:38 AM ET)
Market Chameleon (Tue, 23-Dec 4:17 AM ET)
MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Mannkind trades on the NASDAQ stock market under the symbol MNKD.
As of November 13, 2026, MNKD stock price declined to $4.13 with 1,557,274 million shares trading.
MNKD has a beta of 2.07, meaning it tends to be more sensitive to market movements. MNKD has a correlation of 0.10 to the broad based SPY ETF.
MNKD has a market cap of $1.33 billion. This is considered a Small Cap stock.
Last quarter Mannkind reported $102 million in Revenue and -$.01 earnings per share. This fell short of revenue expectation by $-6 million and exceeded earnings estimates by $.01.
In the last 3 years, MNKD traded as high as $7.63 and as low as $2.23.
The top ETF exchange traded funds that MNKD belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
MNKD has underperformed the market in the last year with a return of -18.5%, while SPY returned +13.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MNKD shares. However, MNKD has outperformed the market in the last 3 month and 2 week periods, returning +10.7% and +18.0%, while SPY returned -2.8% and -0.2%, respectively. This indicates MNKD has been having a stronger performance recently.
MNKD support price is $4.01 and resistance is $4.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNKD shares will trade within this expected range on the day.
